— Know what they know.
Not Investment Advice

SER

Serina Therapeutics, Inc.
1W: +63.9% 1M: +46.8% 3M: -13.6% YTD: +22.1% 1Y: -42.7% 3Y: -88.2% 5Y: -96.3%
$2.54
+0.06 (+2.42%)
After Hours: $2.53 (-0.01, -0.44%)
AMEX · Healthcare · Biotechnology · $27.4M · Alpha Radar Neutral · Power 50
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$27.4M
52W Range1.22-7.92
Volume13,190,235
Avg Volume1,513,284
Beta1.25
Dividend
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOSteven A. Ledger
Employees12
SectorHealthcare
IndustryBiotechnology
IPO Date2000-01-21
601 Genome Way
Huntsville, AL 35806
US
256 327 9630
About Serina Therapeutics, Inc.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Recent Insider Trades

NameTypeSharesPriceDate
Moreadith Randall M-Exempt 39,000 $0.06 2026-03-19
Moreadith Randall S-Sale 39,000 $2.50 2026-03-19
Moreadith Randall M-Exempt 39,000 $0.06 2026-03-19
LEDGER STEVEN A A-Award 230,100 $2.76 2026-02-03
Moreadith Randall A-Award 69,000 $2.76 2026-02-03

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms